CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.46M | 864.00K | 889.00K | 892.00K | 865.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.46M | 864.00K | 889.00K | 892.00K | 865.00K |
| Cost of Revenue | 114.52M | 137.23M | 116.02M | 115.05M | 129.99M |
| Gross Profit | -113.07M | -136.37M | -115.13M | -114.16M | -129.13M |
| SG&A Expenses | 17.18M | 18.40M | 16.93M | 18.92M | 19.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 131.71M | 155.63M | 132.95M | 133.96M | 149.29M |
| Operating Income | -130.25M | -154.76M | -132.06M | -133.07M | -148.42M |
| Income Before Tax | -122.09M | -130.00M | -105.82M | -207.26M | -134.89M |
| Income Tax Expenses | 839.00K | 614.00K | 619.00K | 1.29M | 1.11M |
| Earnings from Continuing Operations | -122.93M | -130.61M | -106.44M | -208.55M | -136.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.93M | -130.61M | -106.44M | -208.55M | -136.00M |
| EBIT | -130.25M | -154.76M | -132.06M | -133.07M | -148.42M |
| EBITDA | -125.93M | -149.10M | -127.63M | -128.42M | -143.69M |
| EPS Basic | -1.28 | -1.37 | -1.17 | -2.40 | -1.58 |
| Normalized Basic EPS | -0.79 | -0.85 | -0.72 | -0.80 | -0.98 |
| EPS Diluted | -1.28 | -1.37 | -1.17 | -2.40 | -1.58 |
| Normalized Diluted EPS | -0.79 | -0.85 | -0.72 | -0.80 | -0.98 |
| Average Basic Shares Outstanding | 96.05M | 95.27M | 91.31M | 87.07M | 85.94M |
| Average Diluted Shares Outstanding | 96.05M | 95.27M | 91.31M | 87.07M | 85.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |